Oct 12, 2023· Comment from Association for Accessible Medicines (AAM)· FDA-2023-D-1954-0005
Comments from the Association for Accessible Medicines (AAM) to Docket No. FDA-2023-D-1954, Classification Categories for Certain Supplements Under the Biosimilar User Fee Amendments of 2022; Draft Guidance for Industry